Lexicon Pharmaceuticals, Inc.LXRXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank87
5Y CAGR+12.7%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
+12.7%/yr
Long-term compound
Percentile
P87
Within normal range
vs 5Y Ago
1.8x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 27.69% |
| Q3 2025 | -240.25% |
| Q2 2025 | 138.82% |
| Q1 2025 | -103.70% |
| Q4 2024 | 59.92% |
| Q3 2024 | -10.46% |
| Q2 2024 | 11.95% |
| Q1 2024 | -9.06% |
| Q4 2023 | -21.45% |
| Q3 2023 | -9.19% |
| Q2 2023 | -20.57% |
| Q1 2023 | -46.57% |
| Q4 2022 | -10.96% |
| Q3 2022 | 20.40% |
| Q2 2022 | -4.27% |
| Q1 2022 | -2.60% |
| Q4 2021 | -33.11% |
| Q3 2021 | 21.62% |
| Q2 2021 | 13.03% |
| Q1 2021 | 26.52% |
| Q4 2020 | 15.20% |
| Q3 2020 | 12.79% |
| Q2 2020 | -109.93% |
| Q1 2020 | 9.51% |
| Q4 2019 | -112.78% |
| Q3 2019 | 808.91% |
| Q2 2019 | -5.00% |
| Q1 2019 | 5.56% |
| Q4 2018 | -22.30% |
| Q3 2018 | 57.77% |
| Q2 2018 | -12.29% |
| Q1 2018 | -38.75% |
| Q4 2017 | 0.74% |
| Q3 2017 | -5.39% |
| Q2 2017 | 62.31% |
| Q1 2017 | -75.23% |
| Q4 2016 | -38.54% |
| Q3 2016 | 26.44% |
| Q2 2016 | -9.46% |
| Q1 2016 | -116.45% |